ALK Positive, Ensartinib, Neoadjuvant Therapy, NSCLC
Conditions
Keywords
ALK Positive, Ensartinib, NSCLC, Neoadjuvant therapy
Brief summary
Explore the efficacy and safety of Ensartinib in neoadjuvant treatment for ALK-positive non-small cell lung cancer in the real world.This is a real-world study of patients receiving enshatinib-based neoadjuvant therapy with R0 resection, divided into retrospective cohort 1, prospective cohort 2, and prospective cohort 3. The dose, duration, and whether to combine or sequentially treat enshatinib were clinical decisions made by the investigator on a patient-specific basis.
Interventions
None listed
Sponsors
Harbin Medical University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Cohort 1: Female or male aged \>=18 years; 2. Cohort 1: Received neoadjuvant treatment with Ensartinib before the project started; 3. Cohort 1: Diagnosed with clinical stage II-III resectable or potentially resectable (T1-4 N2 M0) ALK-positive NSCLC before neoadjuvant treatment; 4. Cohort 1: Confirmed ALK positive by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), or other non-specific sequencing methods before receiving ALK inhibitor therapy. 5. Cohort 2: Female or male aged \>=18 years; 6. Cohort 2: Intended to receive Ensartinib monotherapy as neoadjuvant treatment for 6-12 weeks; 7. Cohort 2: Diagnosed with clinical stage II-III resectable or potentially resectable (T1-4 N2 M0) ALK-positive NSCLC before neoadjuvant treatment; 8. Cohort 2: Confirmed ALK positive by immunohistochemistry (IFL), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), or other non-specific sequencing methods before receiving ALK inhibitor therapy; 9. Cohort 2: Signed informed consent form; 10. Cohort 3: Female or male aged \>=18 years; 11. Cohort 3: Intended to receive neoadjuvant treatment including Ensartinib, but not meeting the inclusion criteria for Cohort 2; 12. Cohort 3: Diagnosed with clinical stage II-III resectable or potentially resectable ALK-positive NSCLC before neoadjuvant treatment; 13. Cohort 3: Confirmed ALK positive by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), or other non-specific sequencing methods before receiving ALK inhibitor therapy; 14. Cohort 3: Signed informed consent form.
Exclusion criteria
1. Cohort 1: Patients who have received treatment with Ensartinib after the project has started; 2. Cohort 1: Patients who have received Ensartinib treatment but have not completed the objective efficacy evaluation according to the follow-up cycle specified by the clinical physician; 3. Cohort 1: History of hypersensitivity reactions to active or inactive excipients of Ensartinib or to drugs with similar chemical structures or categories as Ensartinib; 4. Cohort 1: Patients who are participating in other clinical studies outside of this research; 5. Cohort 1: Other circumstances deemed unsuitable for enrollment by the researchers. 6. Cohort 2: Patients who have received Ensartinib treatment before the study started; 7. Cohort 2: Patients who have received other systemic treatments besides Ensartinib; 8. Cohort 2: Neoadjuvant treatment cycles less than 6 weeks or more than 12 weeks; 9. Cohort 2: Patients who have received Ensartinib monotherapy but have not completed the objective efficacy evaluation according to the follow-up cycle specified by the clinical physician; 10. Cohort 2: History of hypersensitivity reactions to active or inactive excipients of Ensartinib or to drugs with similar chemical structures or categories as Ensartinib; 11. Cohort 2: Patients who are participating in other clinical studies outside of this research; 12. Cohort 2: Other circumstances deemed unsuitable for enrollment by the researchers. 13. Cohort 3: Patients who have received neoadjuvant treatment containing Ensartinib but meet the enrollment criteria for Cohort 2; 14. Cohort 3: Patients who have received treatment containing Ensartinib but have not completed the objective efficacy evaluation according to the follow-up cycle specified by the clinical physician; 15. Cohort 3: History of hypersensitivity reactions to active or inactive excipients of Ensartinib or to drugs with similar chemical structures or categories as Ensartinib; 16. Cohort 3: Patients who are participating in other clinical studies outside of this research; 17. Cohort 3: Other circumstances deemed unsuitable for enrollment by the researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MPR | 6month | Main pathological remission rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pCR | 6month | Pathological complete response rate |
| 2-year disease-free survival rate | 2year | 2-year disease-free survival rate |
| ORR | 1year | Objective response rate |
Contacts
Primary ContactMa
Outcome results
None listed